Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Update

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 40,719 shares, a growth of 64.3% from the December 31st total of 24,781 shares. Based on an average daily volume of 51,051 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.8% of the shares of the company are sold short. Approximately 0.8% of the shares of the company are sold short. Based on an average daily volume of 51,051 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Investors Weigh In On Neuphoria Therapeutics

A number of hedge funds have recently bought and sold shares of NEUP. Persistent Asset Partners Ltd bought a new position in Neuphoria Therapeutics during the 3rd quarter valued at $58,000. FNY Investment Advisers LLC bought a new position in Neuphoria Therapeutics in the fourth quarter worth about $102,000. Finally, Millennium Management LLC acquired a new position in Neuphoria Therapeutics during the 3rd quarter valued at approximately $216,000. Institutional investors and hedge funds own 15.90% of the company’s stock.

Neuphoria Therapeutics Price Performance

Shares of Neuphoria Therapeutics stock remained flat at $4.02 during trading hours on Friday. 21,692 shares of the stock traded hands, compared to its average volume of 45,678. Neuphoria Therapeutics has a 52 week low of $3.64 and a 52 week high of $21.40. The firm has a market cap of $21.63 million, a P/E ratio of -0.82 and a beta of 0.51. The firm has a fifty day moving average price of $4.08 and a two-hundred day moving average price of $7.58.

Neuphoria Therapeutics (NASDAQ:NEUP) last issued its earnings results on Friday, November 14th. The company reported ($4.41) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($3.86). Analysts anticipate that Neuphoria Therapeutics will post -1.56 EPS for the current year.

Analyst Upgrades and Downgrades

NEUP has been the subject of several recent analyst reports. Wall Street Zen cut shares of Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 23rd. HC Wainwright decreased their target price on Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, December 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, January 22nd. Finally, Zacks Research lowered Neuphoria Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, December 8th. Two analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $21.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.